Trial intelligence / Profile preview

Neratinib vs placebo as adjuvant therapy after trastuzumab in HER2-positive early breast cancer

CTR20181596Phase 3Completed

Sponsor

Puma Biotechnology, Inc.

Start

Dec 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1